OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0000882104

PDL BIOPHARMA, INC.

PDL BIOPHARMA, INC. (CIK 0000882104, EIN 94-3023969) reported revenue of $30.71 million ($30,706,000) for FY2019 (2019-01-01 to 2019-12-31) and net income of -$70.41 million (-$70,411,000) for FY2019 (2019-01-01 to 2019-12-31), as filed in its 10-K filed 2021-03-29 (accession 0000882104-21-000035).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0000882104
EIN94-3023969
SIC industry code2836 Biological Products, (No Diagnostic Substances)
State or country of incorporationDE
Fiscal year endDecember 31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
Olympus entity IDorg_4hm0ck17aset4thxhgsxg710rs
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$30,706,000FY20192019-01-01 to 2019-12-3110-K2021-03-290000882104-21-000035Revenues
Net income-$70,411,000FY20192019-01-01 to 2019-12-3110-K2021-03-290000882104-21-000035NetIncomeLoss
Total assets$717,206,000FY2019as of 2019-12-3110-K2021-03-290000882104-21-000035Assets
Total liabilities$123,928,000FY2019as of 2019-12-3110-K2021-03-290000882104-21-000035Liabilities
Stockholders' equity$593,200,000FY2019as of 2019-12-3110-K2021-03-290000882104-21-000035StockholdersEquity
Operating cash flow-$32,443,000FY20192019-01-01 to 2019-12-3110-K2020-03-110000882104-20-000032NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$0.59 per shareFY20192019-01-01 to 2019-12-3110-K2021-03-290000882104-21-000035EarningsPerShareDiluted
Shares outstanding114,515,806 sharesFY2020as of 2021-01-0610-K2021-03-290000882104-21-000035EntityCommonStockSharesOutstanding
  • Revenue for FY2019 was restated: first reported as $54,757,000 (accession 0000882104-20-000032, filed 2020-03-11).
  • Total assets for FY2019 was restated: first reported as $716,119,000 (accession 0000882104-20-000032, filed 2020-03-11).
  • Total liabilities for FY2019 was restated: first reported as $122,841,000 (accession 0000882104-20-000032, filed 2020-03-11).
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2011-2020, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20192019-01-01 to 2019-12-31$30,706,00010-K2021-03-290000882104-21-000035
RevenueFY20182018-01-01 to 2018-12-31$32,028,00010-K2021-03-290000882104-21-000035
RevenueFY20172017-01-01 to 2017-12-31$320,060,00010-K2020-03-110000882104-20-000032
RevenueFY20162016-01-01 to 2016-12-31$244,301,00010-K2019-03-150000882104-19-000016
RevenueFY20152015-01-01 to 2015-12-31$590,448,00010-K2018-03-160000882104-18-000012
RevenueFY20142014-01-01 to 2014-12-31$581,225,00010-K2017-03-010000882104-17-000013
RevenueFY20132013-01-01 to 2013-12-31$456,260,00010-K2016-02-230000882104-16-000112
RevenueFY20122012-01-01 to 2012-12-31$380,880,00010-K2015-02-230000882104-15-000019
RevenueFY20112011-01-01 to 2011-12-31$362,041,00010-K2014-03-030000882104-14-000006
Net incomeFY20192019-01-01 to 2019-12-31-$70,411,00010-K2021-03-290000882104-21-000035
Net incomeFY20182018-01-01 to 2018-12-31-$68,859,00010-K2021-03-290000882104-21-000035
Net incomeFY20172017-01-01 to 2017-12-31$110,748,00010-K2020-03-110000882104-20-000032
Net incomeFY20162016-01-01 to 2016-12-31$63,606,00010-K2019-03-150000882104-19-000016
Net incomeFY20152015-01-01 to 2015-12-31$332,795,00010-K2018-03-160000882104-18-000012
Net incomeFY20142014-01-01 to 2014-12-31$322,244,00010-K2017-03-010000882104-17-000013
Net incomeFY20132013-01-01 to 2013-12-31$264,530,00010-K2016-02-230000882104-16-000112
Net incomeFY20122012-01-01 to 2012-12-31$211,669,00010-K2015-02-230000882104-15-000019
Net incomeFY20112011-01-01 to 2011-12-31$199,389,00010-K2014-03-030000882104-14-000006
  • Revenue for FY2019 was restated: first reported as $54,757,000 (accession 0000882104-20-000032, filed 2020-03-11).
  • Revenue for FY2018 was restated: first reported as $198,110,000 (accession 0000882104-19-000016, filed 2019-03-15).
  • Revenue for FY2013 was restated: first reported as $442,921,000 (accession 0000882104-14-000006, filed 2014-03-03).
  • Revenue for FY2012 was restated: first reported as $374,525,000 (accession 0001445305-13-000433, filed 2013-03-01).

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-K2021-03-292020-12-310000882104-21-000035pdli-20201231.htm
10-Q2020-11-132020-09-300000882104-20-000181pdli-20200930.htm
10-Q2020-08-072020-06-300000882104-20-000120pdli-20200630.htm
10-Q2020-05-112020-03-310000882104-20-000071pdli-2020033110qdoc.htm
10-K/A2020-04-292019-12-310001104659-20-053337tm2017850-1_10ka.htm
10-K2020-03-112019-12-310000882104-20-000032pdli1231201910-kdoc.htm
10-Q2019-11-062019-09-300000882104-19-000111pdli-2019093010qdoc.htm
10-Q2019-08-072019-06-300000882104-19-000089pdli-2019063010qdoc.htm
10-Q2019-05-092019-03-310000882104-19-000054pdli-2019033110qdoc.htm
10-K2019-03-152018-12-310000882104-19-000016pdli1231201810-kdoc.htm
10-Q2018-11-072018-09-300000882104-18-000117pdli-2018093010qdoc.htm
10-Q2018-08-092018-06-300000882104-18-000091pdli-2018063010qdoc.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0000882104published by the sourcedata.sec.gov/submissions/CIK0000882104.json2026-10-21

Former names

NameFromTo
PROTEIN DESIGN LABS INC/DE1994-02-142006-01-19

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0000882104.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0000882104.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000882104" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000882104/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000882104/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"882104"}

On SEC EDGAR

About this data